Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.44 |
| ▸ | BRS3 | P32247 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8974321 | 0.89 | CNR1 (0.54) | SMN1; SMN2RAB9AMEN1KMT2AMAPT | |
| SCHEMBL1625320 | 0.84 | CNR1 (0.47) | HTTCNR1CNR2KCNN4BRS3 | |
| SCHEMBL5877921 | 0.83 | MAPT (0.50) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL5097918 | 0.83 | MAOB (0.57) | SMN1; SMN2MEN1KMT2AMAPTHTT | |
| SCHEMBL31612944 | 0.82 | SMN1; SMN2 (0.47) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL31612949 | 0.82 | SMN1; SMN2 (0.47) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL16795995 | 0.82 | SMN1; SMN2 (0.47) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL3573740 | 0.82 | CNR1 (0.53) | MAPTCNR1CNR2KCNN4BRS3 | |
| SCHEMBL11838241 | 0.82 | SMN1; SMN2 (0.46) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL1107149 | 0.82 | CNR2 (0.57) | RAB9ANPC1MAPTCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-20210139467-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-20210139467-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3645512-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-05-06 | — | — | EP | disclosed |
| CN-110785408-A | Modulators of indoleamine2, 3-dioxygenase | 葛兰素史克知识产权开发有限公司 | 2020-02-11 | — | — | CN | disclosed |
| CN-110092804-A | A kind of purine compound and preparation method thereof containing bicyclic radicals | 广州盈升生物科技有限公司 | 2019-08-06 | — | — | CN | disclosed |
| WO-2019003143-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-03 | — | — | WO | disclosed |
| WO-2019003143-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-01-03 | — | — | WO | disclosed |
| US-20180280422-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. | 2018-10-04 | — | — | US | disclosed |
| US-8394819-B2 | Indole derivatives as CRTH2 receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-03-12 | — | — | US | disclosed |
| EP-2492267-A1 | Indole derivatives as CRTH2 receptor antagonists in combination with a second active ingredient | Merck Sharp & Dohme Corp. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2012075381-A1 | SUBSTITUTED PURINE AND 7 - DEAZAPURINE COMPOUNDS AS MODULATORS OF EPIGENETIC ENZYMES | Epizyme, Inc. (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012075381-A1 | SUBSTITUTED PURINE AND 7 - DEAZAPURINE COMPOUNDS AS MODULATORS OF EPIGENETIC ENZYMES | Epizyme, Inc. (US) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2401269-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20100234415-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-09-16 | — | — | US | disclosed |
| WO-2010099039-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280422-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | SMN1; SMN2 434/4885RAB9A 2031/4885NPC1 1157/4885 |
| US-20100234415-A1 | INDOLE DERIVATIVES AS CRTH2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, PTGDR | SMN1; SMN2 4820/4885RAB9A 3377/4885NPC1 3382/4885 |
| US-20210139467-A1 | MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, TPH1 | SMN1; SMN2 2957/4885RAB9A 3849/4885NPC1 984/4885 |
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | SMN1; SMN2 434/4885RAB9A 2031/4885NPC1 1157/4885 |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | SMN1; SMN2 434/4885RAB9A 2031/4885NPC1 1157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.